# Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

> **NCT05274087** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT05274087
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-15
- **Primary completion:** 2021-04-07
- **Final completion:** 2021-04-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05274087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05274087, "Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05274087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*